Compared to a study that also explored the functional and prognostic roles of E2Fs in human prostate cancer (Wang et al., 2021), we further conducted a Kaplan-Meier analysis using biochemical recurrence (BCR)-free survival, which is a critical index to judge the prognosis of patients with PCa, and established a novel predictive prognostic model that combines E2F1, E2F6, Gleason score, and clinical stage and may be useful for future clinical practices. This evidence concerns the gene E2F6 and prostate carcinoma.